30% of Americans are living with some form of chronic or severe pain.
More people live with CHRONIC PAIN than CANCER, HEART DISEASE, and DIABETES, combined.
300% increase in opioid prescriptions in the last decade
1 in 4 patients become addicted to opioids
More than $560B spent annually on healthcare due to pain disorders
121 Americans die every day from an opioid overdose
We have developed a gene therapy to target pain that is non-addictive, highly specific, and long-lasting.
We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain. In our proof of concept, we have demonstrated our therapy increases pain tolerance and lowers pain levels.
Founded in 2018, Navega Therapeutics Inc. is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. Our gene therapy platform has the advantage of being highly specific and long-lasting, which has not been achieved by small molecules thus far. Our pipeline includes different types of pain to improve the quality of life of millions of patients.
Ana Moreno PhD
Founder & CEO
Ana Moreno is the founder and CEO of Navega Therapeutics. She obtained her Ph.D. from the Bioengineering Department at UCSD , where she spent the last four years developing the platform that enables Navega’s innovative approach.
Fernando Aleman PhD
Co-founder & CSO
Fernando obtained his PharmD degree at University of Granada and his PhD at University of Murcia. After postdoc training at UCSD and the Scripps, he leverages his pharmaceutical and industry background to provide medical oversight and strategic direction.
Prashant Mali PhD
Prashant is an assistant professor in the Department of Bioengineering at the UC San Diego. Research in his laboratory lies at the interface of basic science and technology development, towards enabling gene and cell based human therapeutics.
Randall E. Woods
Randall E. Woods is a serial life science entrepreneur, pharmaceutical and biotechnology executive. Mr. Woods brings more than 40 years of experience to the biotech/pharmaceutical arena, and currently serves as the CEO of Sophiris Bio (NASDAQ: SPHS).
Tony L. Yaksh PhD
Tony is Professor in Anesthesiology and Pharmacology at UC San Diego (1988-present). His studies (> 850 papers) provide a basis for understanding the pharmacology of pain processing, focused on spinal systems and delivery of neuraxial therapeutics.